Dare Bioscience, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Dare Bioscience, Inc. (DARE) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.79 per share for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-12.
Discontinued › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2019-11-12
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-31 was $0.76, a 67.93% decline year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2018-03-31 was $2.37, a 189.02% increase year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2017-03-31 was $0.82, a 72.48% decline year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $2.98, a 66.55% decline year-over-year.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2017 was $32.90, a 1668.82% increase from fiscal 2016.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2016 was $1.86, a 67.14% decline from fiscal 2015.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2015 was $5.66, a 5.51% decline from fiscal 2014.
- Dare Bioscience, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2014 was $5.99.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 7 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2019-09-30 | $0.79 10-Q · filed 2019-11-12 | ||||
| 2019-06-30 | $0.79 10-Q · filed 2019-08-14 | ||||
| 2019-03-31 | $0.76 10-Q · filed 2019-05-14 | ||||
| 2018-09-30 | $1.09 10-Q · filed 2018-11-13 | ||||
| 2018-06-30 | $1.68 10-Q · filed 2018-08-13 | ||||
| 2018-03-31 | $2.37 10-Q · filed 2018-05-14 | ||||
| 2017-12-31 | $32.90 10-K · filed 2018-03-28 | ||||
| 2017-09-30 | $8.11 10-Q · filed 2017-11-13 | ||||
| 2017-06-30 | $8.20 10-Q · filed 2017-08-14 | ||||
| 2017-03-31 | $0.82 10-Q · filed 2017-05-12 | ||||
| 2016-12-31 | $1.86 10-K/A · filed 2017-06-13 | ||||
| 2016-09-30 | $1.88 10-Q · filed 2016-11-03 | ||||
| 2016-06-30 | $2.78 10-Q · filed 2016-08-04 | ||||
| 2016-03-31 | $2.98 10-Q · filed 2016-05-02 | ||||
| 2015-12-31 | $0.00 8-K/A · filed 2017-10-02 | $5.66 10-K · filed 2016-03-10 | |||
| 2015-09-30 | $7.35 10-Q · filed 2015-11-16 | ||||
| 2015-06-30 | $7.81 10-Q · filed 2015-08-06 | ||||
| 2015-03-31 | $8.91 10-Q · filed 2015-05-06 | ||||
| 2014-12-31 | $5.99 10-K · filed 2015-03-19 | ||||
| 2014-09-30 | $6.61 10-Q · filed 2014-11-13 | ||||
| 2014-06-30 | $6.81 10-Q · filed 2014-08-12 | ||||
| 2014-03-31 | $10.59 10-Q · filed 2014-05-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |